None listed
Conditions
Interventions
Drug : The study population will consist of patients diagnosed with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI), achieve complete revascularization (CR) of all c
Sponsors
Gyeongsang National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older 2. Patients diagnosed with acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina 3. Patients who have successfully completed intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) 4. Patients who can be randomized within 96 hours after PCI 5. Patients who provide written informed consent for study participation
Exclusion criteria
Exclusion criteria: 1. Planned staged percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) 2. Failed PCI, including no-reflow, major dissection, thrombus, or other procedural complications 3. Requirement for oral anticoagulant (OAC) therapy 4. History of major bleeding within the previous 30 days 5. History of hemorrhagic stroke or ischemic stroke within the previous 6 months 6. Platelet count <100,000/mm³ or white blood cell count <3,000/mm³ 7. Contraindication to aspirin, prasugrel, or ticagrelor 8. Life expectancy of less than 1 year 9. Current pregnancy, potential pregnancy, or lactation 10. Any condition that, in the investigator’s judgment, makes the patient inappropriate for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events: defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization.;Clinically relevant bleeding: defined as the incidence of Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding events occurring up to 12 months after randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of major and minor bleeding according to Thrombolysis in Myocardial Infarction (TIMI) criteria;Incidence of major and minor bleeding according to International Society on Thrombosis and Haemostasis (ISTH) criteria;Incidence of all-cause death;Incidence of myocardial infarction;Incidence of ischemia-driven revascularization;Incidence of stent thrombosis;Incidence of net adverse clinical events;All-cause rehospitalization rate;Medication adherence;Survival rate at 12 months | — |
Countries
Korea, Republic of
Contacts
Public ContactHangyul Kim
Gyeongsang National University Hospital
Outcome results
None listed